Glaukos (GKOS) Fundamentals 2026 — Revenue Analysis | SniperIQ

51.68 on the NYSE. This SniperIQ fundamentals page covers Glaukos's valuation, profitability (net margin -34.3%), revenue ($507M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Glaukos's market cap?

Glaukos (GKOS) has a market capitalization of approximately $8.9B, trading at

51.68 on the NYSE. Market cap moves with the live share price.

What is Glaukos's P/E ratio?

Glaukos's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 13.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Glaukos?

Glaukos runs a net profit margin of -34.3%, a gross margin of 78.1%, and an operating margin of -15.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Glaukos generate?

Glaukos reported revenue of $507M for fiscal year 2025, with net income of -

88M and earnings per share (EPS) of -3.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Glaukos pay a dividend?

Glaukos does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Glaukos financially healthy?

Glaukos carries a debt-to-equity ratio of 0.15x and a current ratio of 5.43x, with a market beta of 0.75. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Glaukos a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Glaukos (GKOS) the key facts are: market cap $8.9B, revenue $507M, 52-week range 73.16-161.53. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.